Junchang Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junchang Qin has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bo Zhang
Department of Ultrasound in Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Chen Dai
Department of Ultrasound, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P. R. China
1 shared publication - Hui Huang
Materdicine Lab, School of Life Sciences Shanghai University Shanghai China
1 shared publication - Min Di
Ultrasound Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
1 shared publication - Ruiming Hu
Department of Ultrasound, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P. R. China
1 shared publication - Wei Feng
Materdicine Lab School of Life Sciences Shanghai University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 27 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (26) , eadu3919
Lysosomal zinc nanomodulation blocks macrophage pyroptosis for counteracting atherosclerosis progression
Macrophage pyroptosis has been identified as a critical pathological mechanism in inflammation-related atherosclerosis (AS). In this work, we have demonstrated that Zn 2+ features the strongest anti-inflammatory performance by screening 10 representative metal ions, and the MTC1 agonists can trigger lysosomal Zn 2+ release and inhibit pyroptosis in macrophages. Based on these findings, we further engineered a mucolipin TRP channel 1 (MTC1)–related therapeutic nanoplatform for endogenously triggering lysosomal zinc release to curb inflammation and block macrophage pyroptosis. This nanoplatform consists of mesoporous silica nanoparticles to deliver MTC1 agonists and carbon nanodots, which could synergistically exert antiatherosclerotic effect by scavenging toxic reactive oxygen species, inhibiting macrophage pyroptosis, modulating macrophage transition, and rebuilding atherosclerotic immune microenvironment. These findings demonstrate that macrophage pyroptosis can be efficiently blocked via leveraging self-lysosomal zinc pool, which provides the paradigm of lysosomal zinc modulation-involved nanotherapeutics for managing other inflammatory diseases.
- 27 June 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (26) , eadu3919
Open AccessLysosomal zinc nanomodulation blocks macrophage pyroptosis for counteracting atherosclerosis progression
Macrophage pyroptosis has been identified as a critical pathological mechanism in inflammation-related atherosclerosis (AS). In this work, we have demonstrated that Zn 2+ features the strongest anti-inflammatory performance by screening 10 representative metal ions, and the MTC1 agonists can trigger lysosomal Zn 2+ release and inhibit pyroptosis in macrophages. Based on these findings, we further engineered a mucolipin TRP channel 1 (MTC1)–related therapeutic nanoplatform for endogenously triggering lysosomal zinc release to curb inflammation and block macrophage pyroptosis. This nanoplatform consists of mesoporous silica nanoparticles to deliver MTC1 agonists and carbon nanodots, which could synergistically exert antiatherosclerotic effect by scavenging toxic reactive oxygen species, inhibiting macrophage pyroptosis, modulating macrophage transition, and rebuilding atherosclerotic immune microenvironment. These findings demonstrate that macrophage pyroptosis can be efficiently blocked via leveraging self-lysosomal zinc pool, which provides the paradigm of lysosomal zinc modulation-involved nanotherapeutics for managing other inflammatory diseases.
- 27 April 2021
- Published by Wiley in Andrologia
- Vol. 53 (7) , e14078
Role of contrast‐enhanced ultrasound with Sonazoid in management of small testicular Leydig cell tumours: A case report with literature review
Small testicular solid lesions are discovered accidentally due to the extensive use of ultrasound in urology and andrology. Early differentiation between benign and malignant testicular neoplasms is crucial for the determination of treatment options, especially for sub‐centimetre lesions. We report a case of a male patient with an incidental discovery of a small testicular lesion on ultrasonography with the chief complaint of left testicular discomfort. The blood‐flow distribution and microbubble dynamics in the lesion were evaluated through contrast‐enhanced ultrasound using Sonazoid intravenous bolus injection, the rapid and intense enhancement pattern tended to be testicular Leydig cell tumour. Through testicular‐sparing surgery, the lesion was excised, and benign testicular Leydig cell tumour was confirmed by post‐operative pathology and immunohistochemical pathology. No sign of recurrence or metastasis was detected during follow‐up.
- 27 April 2021
- Published by Wiley in Andrologia
- Vol. 53 (7) , e14078
Role of contrast‐enhanced ultrasound with Sonazoid in management of small testicular Leydig cell tumours: A case report with literature review
Small testicular solid lesions are discovered accidentally due to the extensive use of ultrasound in urology and andrology. Early differentiation between benign and malignant testicular neoplasms is crucial for the determination of treatment options, especially for sub‐centimetre lesions. We report a case of a male patient with an incidental discovery of a small testicular lesion on ultrasonography with the chief complaint of left testicular discomfort. The blood‐flow distribution and microbubble dynamics in the lesion were evaluated through contrast‐enhanced ultrasound using Sonazoid intravenous bolus injection, the rapid and intense enhancement pattern tended to be testicular Leydig cell tumour. Through testicular‐sparing surgery, the lesion was excised, and benign testicular Leydig cell tumour was confirmed by post‐operative pathology and immunohistochemical pathology. No sign of recurrence or metastasis was detected during follow‐up.